Merck stock up 11% YTD as Keytruda growth, pipeline gains and M&A lift outlook, but patent risks, Gardasil slump and generics weigh on near-term upside.

Merck stock skidded Tuesday — while also buoying Exelixis — after the Dow Jones pharma outlet said a triple approach to ...

A bullish diagonal spread is an advanced option trade and generally not suitable for beginners, but it can have its place ...

Merck (MRK)’s stock surged by 41% over the past six months, driven not significantly by revenue, but rather by increased profits and heightened investor confidence. Following crucial Q3 earnings ...

In the closing of the recent trading day, Merck (MRK) stood at $117.1, denoting a -1.65% move from the preceding trading day.

In the trailing-twelve-months (TTM) as of 3/24/26, 64% of the companies in the S&P 500 reported GAAP Earnings that are lower ...

Merck’s MRK stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since early November, indicating sustained bullish momentum. The 50-day moving average is a short-term ...

Merck (NYSE:MRK) shares snapped six straight sessions of gains, as the stock was down 0.3% at $84.66 on Wednesday. The pharmaceutical giant added nearly 6% in the preceding six sessions. The stock has ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...